Correction to: J Exp Clin Cancer Res 40, 364 (2021).
https://doi.org/10.1186/s13046-021-02154-8
Following publication of the original article [1], the authors identified errors Figs. 3, 4, 5 and 6 specifically:
Figure 3d - Percentage of HCC cells in G0/G1, S and G2/M phase of the cell cycle by PI staining and flow cytometry analysis. Data are expressed as mean ± SD of at least three independent experiments and analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT
Figure 4b - Quantitative analysis and representative pictures of in vivo bioluminescence imaging analysed before administration of compounds (day 0) and during treatments at days 14, 21, 28 or 35. Luminescent signals are expressed as mean ± SD of total flux of photons/sec/cm2/steradian (p/s/cm2/sr). Data were analysed by ANOVA test. (**p < 0.01 n = 6). Representative images of immunofluorescence for PCNA (in red)
Figure 5a, b, c - Heatmap representation of the expression of up-regulated; cancer-related genes in HepG2 and Huh7 cells in TAE226 > SOR compared to NT cells; Venn diagrams showing the overlapping of up-regulated (upper circles) and down-regulated (lower circles) genes in HepG2 and Huh7 cells treated with TAE226 > SOR compared to NT cells.
Figure 6c - EZH2 expression after treatments, in HepG2 and Huh7 cells. αTubulin served as loading control. Values are the mean of arbitrary units ± SD of at least three independent experiments. Data were analysed by 2-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 vs. NT
In addition, the revised Supplementary materials also need to be corrected specifically, Additional files 6, 7 and 8.
The authors provided the Journal with the original data files. The corrected figures are given here. The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.
Supplementary Information
Footnotes
Ilaria Romito, Manuela Porru and Maria Rita Braghini co-first authors.
Reference
- 1.Romito I, Porru M, Braghini MR, et al. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res. 2021;40:364. doi: 10.1186/s13046-021-02154-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.